IKT - Inhibikase Therapeutics, Inc.

1.84
-0.135   -7.337%

Share volume: 139,629
Last Updated: 04-04-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.06%

PREVIOUS CLOSE
CHG
CHG%
$1.98
-0.14
-0.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
35%
Profitability 25%
Dept financing 12%
Liquidity 75%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-15.60%
1 Month
-6.12%
3 Months
-42.68%
6 Months
47.20%
1 Year
-16.74%
2 Year
-42.69%
Key data
Stock price
$1.84
P/E Ratio 
0.00
DAY RANGE
$1.76 - $1.93
EPS 
-$2.55
52 WEEK RANGE
$1.12 - $4.20
52 WEEK CHANGE
-$16.74
MARKET CAP 
218.376 M
YIELD 
N/A
SHARES OUTSTANDING 
7.464 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
0.84
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$148,110
AVERAGE 30 VOLUME 
$130,826
Company detail
CEO: Milton H. Werner
Region: US
Website: inhibikase.com
Employees: 6
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD.

Recent news
loading